Cloud-based platform provides real-time data insights for clinical trials
eClinical Insights, a leading-edge provider of cloud-based clinical trials software, announced today the launch of its eClinical Intelligence Platform. Built upon a first-in-class eClinical data hub that acquires and integrates data from any clinical system, and powered by a business analytics engine, the eClinical Insights platform delivers real-time clinical trial intelligence and workflow capabilities through a suite of cloud-based applications designed to help pharmaceutical, biotech, medical device, and contract research organizations improve the performance of their clinical trials through real-time data sharing and collaboration.
“With the average clinical trial using of 5-7 different clinical systems, one of the critical business challenges the industry faces today is turning these siloes of data into operational intelligence," said Peg Regan, President & CEO of eClinical Insights. “Our platform automatically leverages these disparate data into actionable information, and delivers it through an integrated suite of role-based applications. By eliminating operational blind spots, our technology platform empowers clinical research professionals with the visibility they need to make rapid, data-driven decisions."
The platform's open architecture includes a library of out-of-the-box interfaces to leading EDC technologies, enabling customers to leverage their existing technology investments as integrated components of the eClinical Insights platform. Delivered through a Software-as-a-Service (SaaS) subscription model, the platform includes a suite of cloud-based trial management applications that are available on per study basis, and can be turned on and off as needed, on both new and ongoing trials.
"We took a small data approach to solving a big data problem, and focused solely on the use of clinical trials data to optimize trial execution and collaboration," said Regan. "With a team that has decades of experience in clinical trials management, and unparalleled experience integrating data from EDC, IVR, ePRO, CTMS, and Central Laboratory systems, we had a unique vantage point from which to solve this challenge. We leveraged this experience in the development of a technology platform that delivers instant visibility across the diverse ecosystem of systems, service providers, and stakeholders of today's clinical trials."
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.